Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a ...

In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a disease in which a buildup of fat causes inflammation and damage to the liver. It used to be called nonalcoholic steatohepatitis (NASH).

HepaStem is also advancing into the clinic in severe NASH. These studies mark the culmination of more than a decade of work to discover and refine liver specific cell-based therapies with ...

Where multiple sensitivity and specificity values are reported, the values providing the highest Youden Index are given (i.e., highest sum of sensitivity and specificity minus one). ALT: Alanine ...

expand Madrigal Pharmaceuticals' NASH pill Rezdiffra is FDA-approved treatment for the fatty liver disease. Madrigal Pharrmaceuticals "I will ask you to look at any [new drug] launch," said Sibold ...

NASH diagnostics consists of CK-18 total, CK-18 cleaved, adiponectin and resistin. NASH diagnostic panel consists of diabetes, gender, BMI, triglyceride and CK-18 total, CK-18 cleaved levels.